Three-Year Experience With KRAS, BRAF, and NRAS Mutations in Colon Cancer: A Single-Center Study

Authors : Ethem Ömeroğlu, Ayşe Nur Uğur Kılınç, Zeynep Bayramoğlu, Yaşar Ünlü

Pages : 1291-1296

Doi:10.54005/geneltip.1763423

View : 46 | Download : 121

Publication Date : 2025-12-31

Article Type : Research Paper

Abstract :Aim: This study aimed to evaluate the molecular mutation profiles of KRAS, BRAF, and NRAS in patients diagnosed with colon adenocarcinoma over the past three years in a single tertiary center, and to assess potential associations between mutation status and clinicopathological parameters such as grade, age, gender, lymph node metastasis, distant metastasis, and tumor size. Materials and Methods: A total of 100 patients diagnosed with colon adenocarcinoma between 2017 and 2020 and who underwent molecular testing were included. KRAS, BRAF, and NRAS mutation results, along with clinical and histopathological data, were retrospectively collected and statistically analyzed. Results: KRAS mutations were detected in 52% of cases, while NRAS and BRAF mutations were identified in 6% and 5% of patients, respectively. No statistically significant associations were found between KRAS mutation status and any of the clinicopathological variables. NRAS mutations were significantly associated with larger tumor diameter (p<0.05). BRAF-mutant tumors were predominantly located in the right colon (80%, p<0.05). Conclusion: Our findings are consistent with previously reported mutation frequencies in the literature. Among the evaluated mutations, only NRAS mutation showed a statistically significant association with tumor size. No other significant prognostic or demographic correlations were observed. These findings contribute to the growing understanding of the molecular landscape in colon cancer and its clinical relevance.
Keywords : KRAS, BRAF, NRAS, Kolon adenokarsinom, Moleküler patoloji

ORIGINAL ARTICLE URL